Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.

IF 33.7 1区 医学 Q1 Medicine Mmwr Recommendations and Reports Pub Date : 2021-01-08 DOI:10.15585/mmwr.rr7001a1
Mary J Choi, Caitlin M Cossaboom, Amy N Whitesell, Jonathan W Dyal, Allison Joyce, Rebecca L Morgan, Doug Campos-Outcalt, Marissa Person, Elizabeth Ervin, Yon C Yu, Pierre E Rollin, Brian H Harcourt, Robert L Atmar, Beth P Bell, Rita Helfand, Inger K Damon, Sharon E Frey
{"title":"Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.","authors":"Mary J Choi,&nbsp;Caitlin M Cossaboom,&nbsp;Amy N Whitesell,&nbsp;Jonathan W Dyal,&nbsp;Allison Joyce,&nbsp;Rebecca L Morgan,&nbsp;Doug Campos-Outcalt,&nbsp;Marissa Person,&nbsp;Elizabeth Ervin,&nbsp;Yon C Yu,&nbsp;Pierre E Rollin,&nbsp;Brian H Harcourt,&nbsp;Robert L Atmar,&nbsp;Beth P Bell,&nbsp;Rita Helfand,&nbsp;Inger K Damon,&nbsp;Sharon E Frey","doi":"10.15585/mmwr.rr7001a1","DOIUrl":null,"url":null,"abstract":"<p><p>This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the rVSVΔG-ZEBOV-GP Ebola vaccine (Ervebo) in the United States. The vaccine contains rice-derived recombinant human serum albumin and live attenuated recombinant vesicular stomatitis virus (VSV) in which the gene encoding the glycoprotein of VSV was replaced with the gene encoding the glycoprotein of Ebola virus species Zaire ebolavirus. Persons with a history of severe allergic reaction (e.g., anaphylaxis) to rice protein should not receive Ervebo. This is the first and only vaccine currently licensed by the Food and Drug Administration for the prevention of Ebola virus disease (EVD). These guidelines will be updated based on availability of new data or as new vaccines are licensed to protect against EVD.ACIP recommends preexposure vaccination with Ervebo for adults aged ≥18 years in the U.S. population who are at highest risk for potential occupational exposure to Ebola virus species Zaire ebolavirus because they are responding to an outbreak of EVD, work as health care personnel at federally designated Ebola treatment centers in the United States, or work as laboratorians or other staff at biosafety level 4 facilities in the United States. Recommendations for use of Ervebo in additional populations at risk for exposure and other settings will be considered and discussed by ACIP in the future.</p>","PeriodicalId":51328,"journal":{"name":"Mmwr Recommendations and Reports","volume":"70 1","pages":"1-12"},"PeriodicalIF":33.7000,"publicationDate":"2021-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802368/pdf/","citationCount":"27","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mmwr Recommendations and Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.rr7001a1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 27

Abstract

This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the rVSVΔG-ZEBOV-GP Ebola vaccine (Ervebo) in the United States. The vaccine contains rice-derived recombinant human serum albumin and live attenuated recombinant vesicular stomatitis virus (VSV) in which the gene encoding the glycoprotein of VSV was replaced with the gene encoding the glycoprotein of Ebola virus species Zaire ebolavirus. Persons with a history of severe allergic reaction (e.g., anaphylaxis) to rice protein should not receive Ervebo. This is the first and only vaccine currently licensed by the Food and Drug Administration for the prevention of Ebola virus disease (EVD). These guidelines will be updated based on availability of new data or as new vaccines are licensed to protect against EVD.ACIP recommends preexposure vaccination with Ervebo for adults aged ≥18 years in the U.S. population who are at highest risk for potential occupational exposure to Ebola virus species Zaire ebolavirus because they are responding to an outbreak of EVD, work as health care personnel at federally designated Ebola treatment centers in the United States, or work as laboratorians or other staff at biosafety level 4 facilities in the United States. Recommendations for use of Ervebo in additional populations at risk for exposure and other settings will be considered and discussed by ACIP in the future.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用埃博拉疫苗:免疫做法咨询委员会的建议,美国,2020年。
本报告总结了免疫实践咨询委员会(ACIP)关于在美国使用rVSVΔG-ZEBOV-GP埃博拉疫苗(Ervebo)的建议。该疫苗含有大米衍生的重组人血清白蛋白和减毒活重组水疱性口炎病毒(VSV),其中编码VSV糖蛋白的基因被编码埃博拉病毒扎伊尔埃博拉病毒糖蛋白的基因所取代。对大米蛋白有严重过敏反应(如过敏反应)史的人不应接受Ervebo。这是美国食品和药物管理局目前批准的第一种也是唯一一种预防埃博拉病毒病的疫苗。这些指南将根据新数据的可用性或新疫苗获得许可以预防埃博拉病毒病而更新。ACIP建议美国人群中年龄≥18岁的成年人在暴露前接种Ervebo疫苗,这些成年人可能因职业暴露于埃博拉病毒扎伊尔埃博拉病毒而面临最高风险,因为他们正在应对埃博拉病毒的爆发,在美国联邦政府指定的埃博拉治疗中心担任卫生保健人员,或在美国生物安全4级设施担任实验室工作人员或其他工作人员。ACIP将在未来考虑和讨论在其他暴露风险人群和其他环境中使用Ervebo的建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Mmwr Recommendations and Reports
Mmwr Recommendations and Reports PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
36.00
自引率
0.00%
发文量
3
期刊介绍: The MMWR series of publications is published by the Office of Science, Centers for Disease Control and Prevention (CDC), U.S. The MMWR Recommendations and Reports contain in-depth articles that relay policy statements for prevention and treatment in all areas in the CDC’s scope of responsibility (e.g., recommendations from the Advisory Committee on Immunization Practices).
期刊最新文献
CDC Program Evaluation Framework, 2024. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season. U.S. Selected Practice Recommendations for Contraceptive Use, 2024. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1